Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Conaghan, PG, Østergaard, M, Troum, O, Bowes, MA, Guillard, G, Wilkinson, B, Xie, Z, Andrews, J, Stein, A, Chapman, D & Koenig, A 2019, 'Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis' Arthritis Research & Therapy, vol. 21, no. 1, pp. 214. https://doi.org/10.1186/s13075-019-2000-1

APA

CBE

MLA

Vancouver

Author

Conaghan, Philip G ; Østergaard, Mikkel ; Troum, Orrin ; Bowes, Michael A ; Guillard, Gwenael ; Wilkinson, Bethanie ; Xie, Zhiyong ; Andrews, John ; Stein, Amy ; Chapman, Douglass ; Koenig, Andrew. / Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. In: Arthritis Research & Therapy. 2019 ; Vol. 21, No. 1. pp. 214.

Bibtex

@article{cb2981e773a54aa68b44669dd3ef805e,
title = "Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis",
abstract = "BACKGROUND: The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and clinical disease activity measures as predictors of later structural progression in early rheumatoid arthritis (RA).METHODS: This was a post hoc analysis of data pooled across treatments from a three-arm (tofacitinib monotherapy, tofacitinib with methotrexate [MTX], or MTX monotherapy) trial of MTX-na{\"i}ve patients with early, active RA. Synovitis, osteitis and erosions were assessed with the Outcome Measures in Rheumatology (OMERACT) RA MRI scoring system (RAMRIS) and RAMRIQ (automated quantitative RA MRI assessment system; automated RAMRIS) at months 0, 1, 3, 6 and 12. Radiographs were assessed at months 0, 6 and 12, and clinical endpoints were assessed at all timepoints. Univariate and multivariate analyses explored the predictive value of early changes in RAMRIS/RAMRIQ parameters and disease activity measures, with respect to subsequent radiographic progression.RESULTS: Data from 109 patients with a mean RA duration of 0.7 years were included. In univariate analyses, changes in RAMRIS erosions at months 1 and 3 significantly predicted radiographic progression at month 12 (both p <  0.01); changes in RAMRIQ synovitis and osteitis at months 1 and 3 were significant predictors of RAMRIS erosions and radiographic progression at month 12 (all p <  0.01). In subsequent multivariate analyses, RAMRIS erosion change at month 1 (p <  0.05) and RAMRIQ osteitis changes at months 1 and 3 (both p <  0.01) were significant independent predictors of radiographic progression at month 12. Univariate analyses demonstrated that changes in Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]) at months 1 and 3 were not predictive of month 12 radiographic progression.CONCLUSIONS: MRI changes seen as early as 1 month after RA treatment initiation have the potential to better predict long-term radiographic progression than changes in disease activity measures.TRIAL REGISTRATION: ClinicalTrials.gov, NCT01164579 .",
author = "Conaghan, {Philip G} and Mikkel {\O}stergaard and Orrin Troum and Bowes, {Michael A} and Gwenael Guillard and Bethanie Wilkinson and Zhiyong Xie and John Andrews and Amy Stein and Douglass Chapman and Andrew Koenig",
note = "COPECARE",
year = "2019",
month = "10",
day = "21",
doi = "10.1186/s13075-019-2000-1",
language = "English",
volume = "21",
pages = "214",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

AU - Conaghan, Philip G

AU - Østergaard, Mikkel

AU - Troum, Orrin

AU - Bowes, Michael A

AU - Guillard, Gwenael

AU - Wilkinson, Bethanie

AU - Xie, Zhiyong

AU - Andrews, John

AU - Stein, Amy

AU - Chapman, Douglass

AU - Koenig, Andrew

N1 - COPECARE

PY - 2019/10/21

Y1 - 2019/10/21

N2 - BACKGROUND: The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and clinical disease activity measures as predictors of later structural progression in early rheumatoid arthritis (RA).METHODS: This was a post hoc analysis of data pooled across treatments from a three-arm (tofacitinib monotherapy, tofacitinib with methotrexate [MTX], or MTX monotherapy) trial of MTX-naïve patients with early, active RA. Synovitis, osteitis and erosions were assessed with the Outcome Measures in Rheumatology (OMERACT) RA MRI scoring system (RAMRIS) and RAMRIQ (automated quantitative RA MRI assessment system; automated RAMRIS) at months 0, 1, 3, 6 and 12. Radiographs were assessed at months 0, 6 and 12, and clinical endpoints were assessed at all timepoints. Univariate and multivariate analyses explored the predictive value of early changes in RAMRIS/RAMRIQ parameters and disease activity measures, with respect to subsequent radiographic progression.RESULTS: Data from 109 patients with a mean RA duration of 0.7 years were included. In univariate analyses, changes in RAMRIS erosions at months 1 and 3 significantly predicted radiographic progression at month 12 (both p <  0.01); changes in RAMRIQ synovitis and osteitis at months 1 and 3 were significant predictors of RAMRIS erosions and radiographic progression at month 12 (all p <  0.01). In subsequent multivariate analyses, RAMRIS erosion change at month 1 (p <  0.05) and RAMRIQ osteitis changes at months 1 and 3 (both p <  0.01) were significant independent predictors of radiographic progression at month 12. Univariate analyses demonstrated that changes in Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]) at months 1 and 3 were not predictive of month 12 radiographic progression.CONCLUSIONS: MRI changes seen as early as 1 month after RA treatment initiation have the potential to better predict long-term radiographic progression than changes in disease activity measures.TRIAL REGISTRATION: ClinicalTrials.gov, NCT01164579 .

AB - BACKGROUND: The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and clinical disease activity measures as predictors of later structural progression in early rheumatoid arthritis (RA).METHODS: This was a post hoc analysis of data pooled across treatments from a three-arm (tofacitinib monotherapy, tofacitinib with methotrexate [MTX], or MTX monotherapy) trial of MTX-naïve patients with early, active RA. Synovitis, osteitis and erosions were assessed with the Outcome Measures in Rheumatology (OMERACT) RA MRI scoring system (RAMRIS) and RAMRIQ (automated quantitative RA MRI assessment system; automated RAMRIS) at months 0, 1, 3, 6 and 12. Radiographs were assessed at months 0, 6 and 12, and clinical endpoints were assessed at all timepoints. Univariate and multivariate analyses explored the predictive value of early changes in RAMRIS/RAMRIQ parameters and disease activity measures, with respect to subsequent radiographic progression.RESULTS: Data from 109 patients with a mean RA duration of 0.7 years were included. In univariate analyses, changes in RAMRIS erosions at months 1 and 3 significantly predicted radiographic progression at month 12 (both p <  0.01); changes in RAMRIQ synovitis and osteitis at months 1 and 3 were significant predictors of RAMRIS erosions and radiographic progression at month 12 (all p <  0.01). In subsequent multivariate analyses, RAMRIS erosion change at month 1 (p <  0.05) and RAMRIQ osteitis changes at months 1 and 3 (both p <  0.01) were significant independent predictors of radiographic progression at month 12. Univariate analyses demonstrated that changes in Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]) at months 1 and 3 were not predictive of month 12 radiographic progression.CONCLUSIONS: MRI changes seen as early as 1 month after RA treatment initiation have the potential to better predict long-term radiographic progression than changes in disease activity measures.TRIAL REGISTRATION: ClinicalTrials.gov, NCT01164579 .

U2 - 10.1186/s13075-019-2000-1

DO - 10.1186/s13075-019-2000-1

M3 - Journal article

VL - 21

SP - 214

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

ER -

ID: 58908250